60 related articles for article (PubMed ID: 26620390)
1. Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.
Miermeister CP; Petersenn S; Buchfelder M; Fahlbusch R; Lüdecke DK; Hölsken A; Bergmann M; Knappe HU; Hans VH; Flitsch J; Saeger W; Buslei R
Acta Neuropathol Commun; 2015 Aug; 3():50. PubMed ID: 26285571
[TBL] [Abstract][Full Text] [Related]
2. Epithelial and organ-related marker expression in pituitary adenomas.
Cykowski MD; Takei H; Baskin DS; Rivera AL; Powell SZ
Neuropathology; 2016 Aug; 36(4):354-64. PubMed ID: 26991787
[TBL] [Abstract][Full Text] [Related]
3. Strategies to use microRNAs as therapeutic targets.
Gentilin E; Degli Uberti E; Zatelli MC
Best Pract Res Clin Endocrinol Metab; 2016 Oct; 30(5):629-639. PubMed ID: 27923456
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Biomarkers in Pituitary Tumours: A Systematic Review.
Papadimitriou E; Chatzellis E; Dimitriadi A; Kaltsas GA; Theocharis S; Alexandraki KI
touchREV Endocrinol; 2023 Nov; 19(2):42-53. PubMed ID: 38187082
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract][Full Text] [Related]
6. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
7. Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors.
Mattogno PP; D'Alessandris QG; Chiloiro S; Bianchi A; Giampietro A; Pontecorvi A; De Marinis L; Olivi A; Anile C; Lauretti L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209686
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.
Tang Y; Xie T; Wu S; Yang Q; Liu T; Li C; Liu S; Shao Z; Zhang X
Endocrine; 2021 Nov; 74(2):375-386. PubMed ID: 34043183
[TBL] [Abstract][Full Text] [Related]
9. [The 2017 WHO classification of pituitary tumors].
Saeger W
Pathologe; 2021 May; 42(3):333-351. PubMed ID: 33877399
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.
Liao X; Han C; Wang X; Huang K; Yu T; Yang C; Huang R; Liu Z; Han Q; Peng T
Cancer Manag Res; 2018; 10():3255-3271. PubMed ID: 30233242
[TBL] [Abstract][Full Text] [Related]
11. Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma.
Liao X; Liu X; Yang C; Wang X; Yu T; Han C; Huang K; Zhu G; Su H; Qin W; Huang R; Yu L; Deng J; Zeng X; Ye X; Peng T
J Cancer; 2018; 9(13):2357-2373. PubMed ID: 30026832
[No Abstract] [Full Text] [Related]
12. Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling.
Yan J; Du P; Jia Y; Chang Z; Gan S; Xu X; Wang Y; Qin Y; Kan Q
Onco Targets Ther; 2018; 11():3323-3333. PubMed ID: 29922071
[TBL] [Abstract][Full Text] [Related]
13. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior.
Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP
Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology.
Garbicz F; Mehlich D; Rak B; Sajjad E; Maksymowicz M; Paskal W; Zieliński G; Włodarski PK
Pituitary; 2017 Aug; 20(4):450-463. PubMed ID: 28432562
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 and minichromosome maintenance-7 (MCM7) expression in canine pituitary corticotroph adenomas.
Ishino H; Hara Y; Takekoshi S; Teshima T; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2011 Nov; 41(4):207-13. PubMed ID: 21982272
[TBL] [Abstract][Full Text] [Related]
17. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
18. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Raverot G; Jouanneau E; Trouillas J
Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
